Rational combinations of ibrutinib and other targeted agents have shown promise in the therapy of R/R MCL including anti-CD20 rituximab, BCL2 inhibitor venetoclax, or CDK4 inhibitor palbociclib [125]. This evidence concerns the gene CDK4 and mantle cell lymphoma.